RecruitingMetastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, Adult
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Eligible age
18+ yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.
Sponsor: Tyra Biosciences, Inc
Where it's recruiting
California
Los Angeles · San Francisco · Stanford
Kansas
Westwood
Maryland
Baltimore
Massachusetts
Boston
Michigan
Detroit
New York
New York
Tennessee
Nashville
Source: ClinicalTrials.gov · NCT06915753 · last updated 2025-11-20